-
Mashup Score: 2AZGP1 deficiency promotes angiogenesis in prostate cancer - Journal of Translational Medicine - 3 hour(s) ago
Background Loss of AZGP1 expression is a biomarker associated with progression to castration resistance, development of metastasis, and poor disease-specific survival in prostate cancer. However, high expression of AZGP1 cells in prostate cancer has been reported to increase proliferation and invasion. The exact role of AZGP1 in prostate cancer progression remains elusive. Method AZGP1 knockout and overexpressing prostate cancer cells were generated using a lentiviral system. The effects of AZGP1 under- or over-expression in prostate cancer cells were evaluated by in vitro cell proliferation, migration, and invasion assays. Heterozygous AZGP1± mice were obtained from European Mouse Mutant Archive (EMMA), and prostate tissues from homozygous knockout male mice were collected at 2, 6 and 10 months for histological analysis. In vivo xenografts generated from AZGP1 under- or over-expressing prostate cancer cells were used to determine the role of AZGP1 in prostate cancer tumor growth, and
Categories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 2New Prostate Cancer Risk Variants Identified in Expanded Multi-Ancestry GWAS Meta-Analysis - Anqi Wang - 5 hour(s) ago
Anqi Wang unveils findings from her study published in Nature Genetics. Dr. Wang’s research marks a significant advance in understanding the genetic landscape of prostate cancer, identifying a total of 451 independent risk loci, including 187 novel variants, through an expanded multi-ancestry meta-analysis. This study not only enlarges the scope of known genetic risk factors but also emphasizes…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 25
Prostate Cancer UK has today announced details of a £42 million screening trial, which aims to find the best way to screen men for prostate cancer and double the number of lives saved.
Source: www.icr.ac.ukCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Multidisciplinary Approach in the Treatment of Metastatic Prostate Cancer - Robert Dreicer - 2 day(s) ago
Program: Beyond Androgen Blockade – New Pathways and Novel Treatments in mHSPC and mCRPC Part of an Independent Medical Education Initiative Supported by LOXO@Lilly Biographies: Robert Dreicer, MD, MS, MACP, FASCO, Head, Medical Oncology Section, Deputy Director University of Virginia Comprehensive Cancer Center, Associate Director for Clinical Research, Co-Director Paul Mellon Urologic Oncology…
Source: www.urotoday.comCategories: General Medicine News, UrologyTweet-
Multidisciplinary approach in the treatment of metastatic #ProstateCancer. @CaPsurvivorship @DanaFarber moderates a discussion and presentation with Robert Dreicer @MedicineUVA in this independent medical education initiative supported by @LoxoLillyOnc > https://t.co/KuAdbDdaHk https://t.co/EfcqRGEkiX
-
-
Mashup Score: 13PSMA PET Imaging and Targeted Therapies: A Case Study on High-Risk Localized Prostate Cancer - Tian Zhang - 2 day(s) ago
Program: State-of-the-Art Interdisciplinary Management of Prostate Cancer This series is part of an Independent Medical Education Initiative Supported by BAYER U.S. LLC PHARMACEUTICALS Biographies: Tian Zhang, MD, MHS, Associate Professor, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX Elena Castro, MD, PhD, Hospital Universitario 12 de Octubre,…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 2Case Series of Men with the Germline APC I1307K Variant and Treatment-Emergent Neuroendocrine Prostate Cancer - Beyond the Abstract - 2 day(s) ago
prostate cancer, Germline APC I1307K mutation, androgen receptor signaling pathway, Treatment-Emergent Neuroendocrine Prostate Cancer, aggressive variant prostate cancer (AVPC), RB1, TP53, PTEN.
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
Case series explores the link between germline APC I1307K variant and treatment-emergent neuroendocrine #ProstateCancer. Discoveries shed light on potential genetic predictors & underline the need for personalized surveillance strategies > https://t.co/CC7Jm3VGpW @minaseconomides https://t.co/9zhksZ7adz
-
-
Mashup Score: 1
Program: Beyond Androgen Blockade – New Pathways and Novel Treatments in mHSPC and mCRPC Part of an Independent Medical Education Initiative Supported by LOXO@Lilly Biographies: A. Oliver Sartor, MD, Disease Group Leader GU Cancers, Director of Radiopharmaceutical Trials, Mayo Clinic, Rochester, MN Neal D. Shore, MD, FACS, Medical Director, Carolina Urologic Research Center, Atlantic Urology…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 3Broadening Treatment Horizons with CDK4/6 Inhibitors from Breast to Prostate Cancer - Rana McKay - 3 day(s) ago
Program: Beyond Androgen Blockade – New Pathways and Novel Treatments in mHSPC and mCRPC Part of an Independent Medical Education Initiative Supported by LOXO@Lilly Biographies: Rana R. McKay, Medical Oncologist, Associate Professor, University of California, San Diego, San Diego, CA Alicia Morgans, MD, MPH , Genitourinary Medical Oncologist, Medical Director of Survivorship Program at…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 19
A single invitation for PSA screening compared with standard practice without routine screening reduced prostate cancer deaths at a median follow-up of 15 years.
Source: prostate.uroonco.uroweb.orgCategories: General Medicine News, UrologyTweet
-
Mashup Score: 16ENZA-p Trial Shows Promise for Enzalutamide-Lutetium Combination in Prostate Cancer - Louise Emmett - 7 day(s) ago
Alicia Morgans speaks with Louise Emmett about the ENZA-p study, presented at ESMO 2023. This groundbreaking research explores the combination of lutetium and enzalutamide in treating early metastatic castrate-resistant prostate cancer. Patients, previously showing limited response to enzalutamide, were screened with PSMA PET and randomized to receive either enzalutamide alone or combined with…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
SCI member James Brooks & others found AZGP1 is a negative regulator of angiogenesis, such that loss of AZGP1 promotes angiogenesis in #ProstateCancer. https://t.co/rLd4tunSwo https://t.co/9o5lDNKkQJ